301 results on '"Santra, Sampa"'
Search Results
2. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
3. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
4. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates
5. Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center
6. Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
7. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
8. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
9. Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques
10. Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs
11. Recombinant Poxvirus Boosting of DNA-Primed Rhesus Monkeys Augments Peak but Not Memory T Lymphocyte Responses
12. Immune checkpoint modulation enhances HIV-1 antibody induction
13. Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination
14. Augmentation of Immune Responses to HIV-1 and Simian Immunodeficiency Virus DNA Vaccines by IL-2/Ig Plasmid Administration in Rhesus Monkeys
15. Control of Viremia in Simian Immunodeficiency Virus Infection by CD8$^+$ Lymphocytes
16. Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques
17. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
18. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection
19. Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection
20. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
21. IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells
22. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
23. Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine
24. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
25. A Centralized Gene-Based HIV-1 Vaccine Elicits Broad Cross-Clade Cellular Immune Responses in Rhesus Monkeys
26. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved
27. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates
28. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies
29. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
30. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses
31. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
32. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
33. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
34. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
35. Cytotoxic effector T cells elicited by the killed tumor vaccine differ significantly from the effectors generated during active growth of a murine B-cell lymphoma
36. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
37. Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques
38. Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition
39. Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization
40. Strong T H 1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy
41. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma
42. Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.
43. Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy.
44. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge
45. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates
46. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models
47. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations
48. Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains
49. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates
50. HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.